AML-399 A Phase 2, Open-Label, Multiarm, Multicenter Study to Evaluate Magrolimab Combined With Antileukemia Therapies for First-Line, Relapsed/Refractory, or Maintenance Treatment of Acute Myeloid Leukemia (AML) (2022)

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s2152-2650(22)01288-5

Publication URI: https://api.elsevier.com/content/abstract/scopus_id/85138168649

Type: Journal Article/Review

Parent Publication: Clinical Lymphoma Myeloma and Leukemia